Literature DB >> 11747258

Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study.

Bernd Heinzl1, Ernst Eber, Béatrice Oberwaldner, Gertrude Haas, Maximilian S Zach.   

Abstract

Inhaled antibiotics are an established treatment for chronic Pseudomonas aeruginosa (PA) infection in patients with cystic fibrosis (CF). However, inhaled antibiotics might also have prophylactic potential to delay acquisition of PA in early stages of the disease. From 1986-1999, all CF patients at this center who experienced defined risk situations for acquisition of PA (28 patients) received inhaled gentamicin (80 mg BID for those < 12 months; 120 mg BID for those > 12 months) for a minimum of 3 years. Twelve patients had repeated risk situations and continued this prophylaxis without interruption during the entire study period (group 1). In the remaining 16 patients, inhaled antibiotics were discontinued at various times for a variety of reasons (group 2). None of the patients in group 1, but 7 in group 2, became chronically infected with PA (P = 0.01). Lung function and chest X-ray scores were significantly worse in those 7 infected patients, when compared to the noninfected ones in both groups. This suggests that long-term-prophylaxis with inhaled gentamicin can effectively delay acquisition of PA and decrease disease progression in children with CF. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11747258     DOI: 10.1002/ppul.10019

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

Review 1.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

2.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

3.  Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Sally Palser; Sherie Smith; Edward F Nash; Arnav Agarwal; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

Review 4.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

Review 5.  Inhaled anti-infective agents: emphasis on colistin.

Authors:  A Michalopoulos; E Papadakis
Journal:  Infection       Date:  2010-02-27       Impact factor: 3.553

Review 6.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

8.  Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2''-phosphotransferases.

Authors:  Marta Toth; Joseph W Chow; Shahriar Mobashery; Sergei B Vakulenko
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

Review 9.  Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Simon C Langton Hewer; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-04-25

10.  Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center.

Authors:  Danish Abdul Aziz; Aiza Abbas; Anusha Alam; Namrah Aziz
Journal:  Lung India       Date:  2022 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.